Business Context and Reporting Period
This Form 8-K is a current report filed by Sunshine Heart, Inc. (not Nuwellis, Inc.) on September 12, 2012. The registrant is a Delaware corporation headquartered in Eden Prairie, Minnesota, operating in the medical device sector. The filing primarily addresses changes to the Board of Directors and related compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation rather than financial performance.
Material Changes
- Election of Director: Jon Erb was elected to the Board of Directors on September 12, 2012. He is scheduled to become Chairman of the Board on October 1, 2012.
- Director Resignation: Nicholas Callinan resigned from the Board effective December 31, 2012. His resignation is not based on any disagreement with the company.
- Committee Assignments: Effective October 1, 2012, Jon Erb will join the Audit, Compensation, and Governance and Nominating committees. Nicholas Callinan will remain on these committees until October 1, 2012.
Compensation and Outlook
Director Compensation:
- Jon Erb: Will receive an annual retainer of AUD$50,000 as a director, increasing to AUD$100,000 upon becoming Chairman on October 1, 2012. He was granted an option to purchase 54,000 shares of common stock at an exercise price of $8.27 per share. The option vests monthly (1/48th) starting October 12, 2012, over a ten-year term.
- Nicholas Callinan: Entered a consulting agreement effective January 1, 2013, expiring March 31, 2015. Compensation includes AUD$2,083.33 per month from January to March 2013, followed by an hourly rate to be determined by the CEO starting April 1, 2013.
Outlook and Risks: The filing does not contain specific guidance, outlook, or risk factors beyond the standard disclosure that Mr. Erb has served on the board of a company (VivoMetrics, Inc.) that filed for Chapter 11 bankruptcy in 2010. No unusual items or contingencies were disclosed.
Investor Verification Checklist
- Verify the exact vesting schedule and conditions for Jon Erb's 54,000 share stock option grant.
- Confirm the final hourly rate to be determined for Nicholas Callinan's consulting services starting April 1, 2013.
- Review the impact of Jon Erb's appointment as Chairman on the company's strategic direction for the medical device sector.
- Check subsequent filings for the formal transition of committee memberships on October 1, 2012.